Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, has announced a US$25 million equity investment from Bristol Myers Squibb (NYSE: BMY) and a term loan facility with access to up to US$125 million from Hercules Capital, Inc. (NYSE: HTGC).

Latham & Watkins LLP represents Hercules Capital, Inc. in the transaction with a transactional team led by Bay Area partners Haim Zaltzman, Dan Van Fleet, and Jim Morrone, with Austin associates Erin Cusenbary and Cooper Shear. Advice was also provided on tax matters by Los Angeles partner Eric Cho; on regulatory matters by Washington, D.C. associate Chad M. Jennings; and on corporate matters by New York partner Reza Mojitabaee-Zamani and associate Eric Rice, and Chicago associate Erica Kucharski .